ClinicalTrials.gg
RecruitingNCT07709013Updated Jul 16, 2026

Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients

A Phase 2 interventional study of Leflunomide 20 mg in Hematologic Malignancies, sponsored by Tata Memorial Centre. Recruiting at 3 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Tata Memorial Centre · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2024, registered Jan 2025).
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Patients undergoing half-matched hematopoietic stem cell transplantation (HSCT) are at high risk of viral reactivation after bone marrow transplantation (BMT). The purpose of this study is to evaluate whether leflunomide can prevent cytomegalovirus (CMV) reactivation in these patients and to assess its safety.

The main questions it aims to answer are -

  1. Does leflunomide prevent cytomegalovirus (CMV) related organ damage?
  2. Does leflunomide prevent a rise in cytomegalovirus (CMV) copy number to more than 2000 copies/ml?
  3. Does leflunomide prevent the need to start pre-emptive therapy for cytomegalovirus (CMV)?
  4. Is it safe to use in bone marrow transplant ( BMT) patients?
  5. Does leflunomide prevent other viral reactivations - like Adeno virus and BK virus?
  6. Does leflunomide affect the risk of acute graft-versus-host disease ( acute GVHD) after bone marrow transplant (BMT)?

What medicine will the patients receive? Patients in study shall receive loading dose of Tab. Leflunomide 100 mg daily for 3 days followed by 20 mg daily orally. Leflunomide will be given till day +180 post transplant or till patient is on immunosuppressant medicines.

Read the detailed description

Introduction :While pre-emptive medications have lowered the frequency of cytomegalovirus (CMV) illness after HSCT, CMV reactivation remains associated with higher mortality. Haploidentical transplant (haplo-HSCT) are high risk transplants, which have increased risk of viral reactivations. Current antiviral treatments, such as ganciclovir, have serious adverse effects and are limited in their use, whereas letermovir is expensive and unavailable in India.

Leflunomide, a medicine, which is used in Rheumatoid arthritis, is a possible alternative due to its antiviral effects and low cost. It may be beneficial at preventing cytomegalovirus (CMV) reactivation, particularly in patients with low viral levels. Furthermore, leflunomide has demonstrated efficacy against BK virus and other DNA viruses, making it a possible multifaceted preventive treatment for high-risk haplo-identical hematopoietic stem cell transplantation (HSCT) recipients.

Hypothesis Leflunomide is effective in decreasing clinically significant CMV(cytomegalovirus) infection after haplo-hematopoietic stem cell transplantation (HSCT)

Target population Patients ≥18 years of age who are undergoing haplo-hematopoietic stem cell transplantation (HSCT) for any malignancy at Tata Memorial centre ACTREC, Mumbai

Aims:

To evaluate efficacy of leflunomide as a prophylactic agent against cytomegalovirus (CMV)reactivation in Haplo-hematopoietic stem cell transplantation (HSCT).

Objectives -

Primary objective To determine the rate of clinically significant CMV infection on prophylactic leflunomide in haplo-HSCT patients till day+180 post HSCT

Secondary objective

  1. To evaluate the safety of post-transplant leflunomide using CTCAE 5.0 grading.
  2. To evaluate the incidence of clinically significant BK virus reactivation in peripheral blood and urine till day+180. Clinically significant BK virus reactivation will be defined as per ECIL-6 guidelines as more than 10\^7 copies (7 log10 gEq/mL) in urine and 10\^3 copies (1000 gEq/mL) in blood will be considered significant thresholds to define BK virus re- activation
  3. To evaluate the incidence of grade III - IV acute GVHD.

Study schema - Single-arm, Phase 2, prospective, interventional study

Administration of study treatment Once neutrophil engraftment has occurred i.e., ANC≥500/mm (on or before day-28), all patients in study shall receive loading dose of Tab. Leflunomide 100 mg daily for 3 days followed by 20 mg daily orally. Leflunomide will be given till day +180 post haplo-HSCT or till patient is on systemic immunosuppression

Timing of dose administration Study therapy should be administered/taken at the same time each day. Tablets are to be swallowed whole (i.e., no crushing or chewing the tablet is allowed). Study therapy may be administered with or without food. If a subject misses a dose, the missed dose should be given as soon as possible during the same day. If more than 18 hours have gone by after the regular dosing time, then the missed dose should be skipped and the normal dosing schedule should be resumed. The next dose should not be doubled in order to "make up" what has been missed.

Investigations During Treatment Monitoring: Weekly cytomegalovirus (CMV) PCR in blood, bi-weekly BK virus PCR in blood and urine, and additional tests as clinically indicated.

Overall study duration - 5 years

02

Conditions studied

  • Hematologic Malignancies

Keywords

  • Cytomegalovirus (CMV) Reactivation
  • Leflunomide
  • haplo-HSCT
  • Haploidentical
  • Hematopoietic stem cell transplant
03

In context

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

This study's planned enrollment of 22 is below the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.

Browse Hematologic Neoplasms studies →

Lead sponsor

Tata Memorial Centre is the lead sponsor of 64 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females undergoing Haplo-identical haematopoetic stem cell transplant.
  2. Age ≥18yrs on the day of signing
  3. Undetectable CMV from plasma sample in preceding 7 days
  4. Patient who has WBC engraftment (>=500/cumm for 3 or more consecutive days).
  5. Within 7 days of WBC engraftment
  6. Adequate liver functions ( / AST less than 5 times and \<=3 times upper limit of normal) at time of starting leflunomide
  7. Understands the study procedures, alternative treatment available, and risks involved with the study, and voluntarily agree to participate by giving written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Known to Leflunomide
  2. History of CMV reactivation in past 1 year
  3. Patient is receiving/has received drug known to have anti CMV activity within in last 7 days [Ganciclovir, valganciclovir, foscarnet, letermovir, acyclovir (at doses >=3200 mg PO per day or >=25 mg/kg IV per day), valacyclovir (at doses \&>=3000 mg PO per day)]
  4. Inadequate renal function ( \<=30 ml/min)
  5. Chronic active (HBsAg+ or any HBV DNA+), , or/and
  6. Any psychiatric condition that might limit the ability of the patient to comply with the protocol
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Leflunomide

    This will be a single arm open label intervention study. Patients who undergo haploidentical transplant, within 7 days of engraftment, will receive leflunomide till day+180 post transplant or till patient is on systemic immunosuppression.

    Drug: Leflunomide 20 mg

Interventions

  • DrugLeflunomideStudies of LeflunomideLeflunomide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients in study shall receive loading dose of Tab Leflunomide 100 mg daily for 3 days followed by 20 mg daily orally. Leflunomide will be given till day 180 + post haploidentical transplant or till patient is on systemic immunosuppression.

06

What researchers measure

Primary outcomes

  1. Number of participants with clinically significant cytomegalovirus (CMV) infection

    Number of participants with clinically significant cytomegalovirus (CMV) infection through Day +180 after hematopoietic stem cell transplantation (HSCT). Clinically significant CMV infection is defined as the occurrence of one or more of the following: Cytomegalovirus (CMV) end-organ disease; Cytomegalovirus (CMV) viremia ≥2,000 copies/mL measured by the central laboratory; or Initiation of pre-emptive anti-CMV therapy at the investigator's discretion.

    Time frame: Through Day +180 post hematopoietic stem cell transplantation (HSCT).

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

    Number of participants experiencing treatment-emergent adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: Day+180 post transplant

  2. Number of participants with clinically significant BK virus reactivation

    Number of participants with clinically significant BK virus reactivation through Day +180 after hematopoietic stem cell transplantation. Clinically significant BK virus reactivation is defined according to European Conference on Infections in Leukaemia (ECIL)-6 criteria as: Urine BK viral load \>10⁷ copies/mL (\>7 log₁₀ genome equivalents/mL), or Blood BK viral load \>10³ copies/mL (\>1,000 genome equivalents/mL).

    Time frame: Day+180 post transplant

  3. Number of participants with Grade III-IV acute graft-versus-host disease

    Number of participants who develop Grade III-IV acute graft-versus-host disease (aGVHD) according to the study-defined grading criteria.

    Time frame: Day+180 post transplant

07

Study locations

1 of 3 sites recruiting
  • Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre
    Navi Mumbai, Maharashtra 410210, India
    Recruiting
    • Lingaraj Nayak, MD, DM · Contactlingarajnayak86@gmail.com · 91-9167294976
    • Sumeet Mirgh, MD, DM · Contactdrsumeetmirgh@gmail.com · 91-8130140245
    • Lingaraj Nayak, MD, DM · Principal investigator
    • Sumeet Mirgh, MD, DM · Sub investigator
  • Advanced Centre for Treatment, Research and Education in Cancer
    Navi Mumbai, Maharashtra 410210, India
    Not yet recruiting
  • Advanced Centre for Treatment, Research and Education in Cancer
    Navi Mumbai, Maharashtra 410210, India
    Not yet recruiting
    • Dr. Lingaraj Nayak, MBBS,MD DM Medical Oncology · Contactlingarajnayak86@gmail.com · 91 22 24177000
    • Dr Sumeet Mirgh, DM medical Oncology · Contactdrsumeetmirgh@gmail.com
    • Dr Lingaraj Nayak, MBBS MD DM Medical Oncology · Principal investigator
08

References and documents

Publications

  • PREVYMIS™ (letermovir) Whitehouse Station, NJ: Merck &amp; Co., Inc.; 2017
  • Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, Miller V, Griffiths PD; Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis. 2017 Jan 1;64(1):87-91. doi: 10.1093/cid/ciw668. Epub 2016 Sep 28. PubMed 27682069 ↗
  • Fox R, Helfgott S (2021). Leflunomide. In St Clair EW (Ed.), UpToDate. https://www.uptodate.com/drug-interactions. Accessed June 01, 2023
  • Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999 Nov 22;159(21):2542-50. doi: 10.1001/archinte.159.21.2542. PubMed 10573044 ↗
  • US Department of Health and Human Services, National Institutes of Health, National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version Study protocol Version -1.1 dated 22/02/2024 17 of 16 5.0 2017. https://ctep.cancer.gov/ protocolDevelopment/electronic_applications/docs/ CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 01 May 2020
  • Matthes-Martin S, Feuchtinger T, Shaw PJ, Engelhard D, Hirsch HH, Cordonnier C, Ljungman P; Fourth European Conference on Infections in Leukemia. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012 Dec;14(6):555-63. doi: 10.1111/tid.12022. Epub 2012 Nov 12. PubMed 23146063 ↗
  • Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood. 2010 Dec 16;116(25):5476-85. doi: 10.1182/blood-2010-04-259291. Epub 2010 Sep 13. PubMed 20837781 ↗
  • Anderson EJ, Guzman-Cottrill JA, Kletzel M, Thormann K, Sullivan C, Zheng X, Katz BZ. High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant. 2008 Mar;12(2):219-27. doi: 10.1111/j.1399-3046.2007.00851.x. PubMed 18307672 ↗
  • Jeffers-Francis LK, Burger-Calderon R, Webster-Cyriaque J. Effect of Leflunomide, Cidofovir and Ciprofloxacin on replication of BKPyV in a salivary gland in vitro culture system. Antiviral Res. 2015 Jun;118:46-55. doi: 10.1016/j.antiviral.2015.02.002. Epub 2015 Mar 16. PubMed 25790744 ↗
  • Cesaro S, Dalianis T, Hanssen Rinaldo C, Koskenvuo M, Pegoraro A, Einsele H, Cordonnier C, Hirsch HH; ECIL-6 Group. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2018 Jan 1;73(1):12-21. doi: 10.1093/jac/dkx324. PubMed 29190347 ↗
  • Bogdanovic G, Priftakis P, Giraud G, Kuzniar M, Ferraldeschi R, Kokhaei P, Mellstedt H, Remberger M, Ljungman P, Winiarski J, Dalianis T. Association between a high BK virus load in urine samples of patients with graft-versus-host disease and development of hemorrhagic cystitis after hematopoietic stem cell transplantation. J Clin Microbiol. 2004 Nov;42(11):5394-6. doi: 10.1128/JCM.42.11.5394-5396.2004. PubMed 15528753 ↗
  • Erard V, Kim HW, Corey L, Limaye A, Huang ML, Myerson D, Davis C, Boeckh M. BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood. 2005 Aug 1;106(3):1130-2. doi: 10.1182/blood-2004-12-4988. Epub 2005 Apr 21. PubMed 15845896 ↗
  • Bernhoff E, Tylden GD, Kjerpeseth LJ, Gutteberg TJ, Hirsch HH, Rinaldo CH. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J Virol. 2010 Feb;84(4):2150-6. doi: 10.1128/JVI.01737-09. Epub 2009 Dec 2. PubMed 19955306 ↗
  • Nesselhauf N, Strutt J, Bastani B. Evaluation of leflunomide for the treatment of BK viremia and biopsy proven BK nephropathy; a single center experience. J Nephropathol. 2016 Jan;5(1):34-7. doi: 10.15171/jnp.2016.06. Epub 2015 Dec 23. PubMed 27047808 ↗
  • Chacko B, John GT. Leflunomide for cytomegalovirus: bench to bedside. Transpl Infect Dis. 2012 Apr;14(2):111-20. doi: 10.1111/j.1399-3062.2011.00682.x. Epub 2011 Oct 9. PubMed 22093814 ↗
  • Andrassy J, Illner WD, Rentsch M, Jaeger G, Jauch KW, Fischereder M. Leflunomide: a treatment option for ganciclovir-resistant cytomegalovirus infection after renal transplantation. NDT Plus. 2009 Apr;2(2):149-51. doi: 10.1093/ndtplus/sfp004. PubMed 25949314 ↗
  • Waldman WJ, Knight DA, Lurain NS, Miller DM, Sedmak DD, Williams JW, Chong AS. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation. 1999 Sep 27;68(6):814-25. doi: 10.1097/00007890-199909270-00014. PubMed 10515382 ↗
  • Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6. PubMed 29211658 ↗
  • Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN; 2017 European Conference on Infections in Leukaemia group. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019 Aug;19(8):e260-e272. doi: 10.1016/S1473-3099(19)30107-0. Epub 2019 May 29. PubMed 31153807 ↗
  • Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020 May 7;135(19):1619-1629. doi: 10.1182/blood.2019000956. PubMed 32202631 ↗
  • Uppuluri R, Subburaj D, Jayaraman D, Swaminathan VV, Mullanfiroze K, Vaidhyanathan L, Raj R. Cytomegalovirus reactivation posthematopoietic stem cell transplantation (HSCT) and type of graft: A step toward rationalizing CMV testing and positively impacting the economics of HSCT in developing countries. Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26639. Epub 2017 May 22. PubMed 28544502 ↗
  • Kothari A, Ramachandran VG, Gupta P, Singh B, Talwar V. Seroprevalence of cytomegalovirus among voluntary blood donors in Delhi, India. J Health Popul Nutr. 2002 Dec;20(4):348-51. PubMed 12659416 ↗
  • Gokarn A, Toshniwal A, Pathak A, Arora S, Bonda A, Punatar S, Nayak L, Dwivedi P, Bhat V, Biswas S, Kelkar R, Kannan S, Khattry N. Use of Leflunomide for Treatment of Cytomegalovirus Infection in Recipients of Allogeneic Stem Cell Transplant. Biol Blood Marrow Transplant. 2019 Sep;25(9):1832-1836. doi: 10.1016/j.bbmt.2019.04.028. Epub 2019 May 2. PubMed 31054984 ↗
  • Zaia JA. Cytomegalovirus infection. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation. West Sussex, UK: Wiley-Blackwell; 2016:1069-1079.
  • Hammerstrom AE, Lombardi LR, Pingali SR, Rondon G, Chen J, Milton DR, Chemaly RF, Champlin RE, Gulbis A, Ciurea SO. Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 Feb;24(2):353-358. doi: 10.1016/j.bbmt.2017.09.018. Epub 2017 Oct 3. PubMed 28986189 ↗
  • Steering Committee Of The Blood And Marrow Transplant Clinical Trials Network. The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Oct;22(10):1747-1757. doi: 10.1016/j.bbmt.2016.07.003. Epub 2016 Jul 11. PubMed 27418009 ↗
  • Jakharia N, Howard D, Riedel DJ. CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies. Curr Treat Options Infect Dis. 2021;13(3):123-140. doi: 10.1007/s40506-021-00253-w. Epub 2021 Jul 21. PubMed 34305463 ↗
  • Ljungman P. Viral Infections in Hematopoietic Stem Cell Transplant Recipients. Allogeneic Stem Cell Transplantation. 2009;505-532. Published 2009 Nov 27. doi:10.1007/978-1-59745- 478-0_29
  • Duver F, Weissbrich B, Eyrich M, Wolfl M, Schlegel PG, Wiegering V. Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis. PLoS One. 2020 Feb 4;15(2):e0228451. doi: 10.1371/journal.pone.0228451. eCollection 2020. PubMed 32017805 ↗

Individual participant data

Plan to share: No — At this time, we do not plan to share individual participant data (IPD) due to concerns regarding patient privacy, the regulatory requirements for data sharing for maintaining patient confidentiality

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Apr 2029, 54 months after the start.

Of 114 non-industry phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 95. This study's planned 54 months is close to that.

Counting every sponsor, half of 136 studies reached it within 57 months; a quarter within 40 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2025
First posted
Jul 16, 2026
StartActual
Oct 18, 2024
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07709013
Lead sponsor
Tata Memorial Centre
Collaborators
Indian Council of Medical Research
Responsible party
Dr Lingaraj Nayak (Professor, Medical Oncology, Tata Memorial Centre) — Principal investigator
First posted
Jul 16, 2026
Start date
Oct 18, 2024
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Jul 16, 2026

Study contacts

Lingaraj Nayak, MD, DM
Contact
lingarajnayak86@gmail.com
91-9167294976
Sumeet Mirgh, MD, DM
Contact
drsumeetmirgh@gmail.com
91-8130140245

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leflunomide

Start the discussion